Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Inclusion criteria:

1. Participants with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma
(ICC).

2. Must have received at least one prior standard-of-care therapy or declined such
therapy.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

4. Must be willing to undergo a biopsy prior to treatment and on Cycle 2 Day 1 (Part 2
only).

5. Adequate bone marrow and organ function.

Exclusion criteria:

1. Uncontrolled significant active infections, except Hepatitis B (HBV) or Hepatitis C
(HCV).

2. Known human immunodeficiency virus (HIV) infection.

3. Presence of gastric or esophageal varices requiring active treatment.

4. Previous treatment with selective FGF19-FGFR4 targeted therapy.

5. Females of childbearing potential, or males who have not had a successful vasectomy,
who are unable or unwilling to follow adequate contraceptive measures.